Tandem CD19/CD22 Dual Targets CAR TCells Bridging Hematopoietic Stem Cells Transplantation Acquires Robust Remission for Relapsed and Refractory B Acute Lymphoblastic Leukemia Patients

被引：2
|
作者：
Cui, Wei [1 ]
Zhang, Xinyue [1 ]
Dai, Haiping [1 ]
Cui, Qingya [1 ]
Yin, Jia [1 ]
Li, Zheng [1 ]
Yu, Lei [2 ]
Kang, Liqing [2 ]
Wu, Depei [1 ]
Tang, Xiaowen [1 ]
机构：
[1] Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Natl Clin Res Ctr Hematol Dis, Suzhou, Peoples R China
[2] Shanghai Unicar Therapy Biomed Technol Co Ltd, Shanghai, Peoples R China
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-152565
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1753
引用
收藏
页数：3
相关论文
共 50 条
  • [41] CD19 chimeric antigen receptor-T cells as bridging therapy to allogeneic hematopoietic cell transplantation improves outcome in patients with refractory/relapsed B-cell acute lymphoblastic leukemia
    Liu, Jie
    Xu, Mengyuan
    Zhang, Xiaoqian
    Zhang, Zhuo
    Zhong, Tao
    Yu, Hongjuan
    Fu, Yueyue
    Meng, Hongbin
    Feng, Jiawei
    Zou, Xindi
    Han, Xueying
    Kang, Liqing
    Yu, Lei
    Li, Limin
    HELIYON, 2024, 10 (13)
  • [42] Daratumumab and venetoclax in combination with chemotherapy provide sustained molecular remission in relapsed/refractory CD19, CD20, and CD22 negative acute B lymphoblastic leukemia with KMT2A-AFF1 transcript
    Voruz, Sophie
    Blum, Sabine
    de Leval, Laurence
    Schoumans, Jacqueline
    Solly, Francoise
    Spertini, Olivier
    BIOMARKER RESEARCH, 2021, 9 (01)
  • [43] Daratumumab and venetoclax in combination with chemotherapy provide sustained molecular remission in relapsed/refractory CD19, CD20, and CD22 negative acute B lymphoblastic leukemia with KMT2A-AFF1 transcript
    Sophie Voruz
    Sabine Blum
    Laurence de Leval
    Jacqueline Schoumans
    Françoise Solly
    Olivier Spertini
    Biomarker Research, 9
  • [44] CD19 CAR-T Cells With Membrane-Bound IL-15 for B-Cell Acute Lymphoblastic Leukemia After Failure of CD19 and CD22 CAR-T Cells: Case Report
    Sun, Yao
    Su, Yongfeng
    Wang, Yizhi
    Liu, Na
    Li, Yuhang
    Chen, Jianlin
    Qiao, Zhuoqing
    Niu, Jingwen
    Hu, Jiangwei
    Zhang, Bin
    Ning, Hongmei
    Hu, Liangding
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [45] Quantitative Systems Pharmacology Modeling to Evaluate and Prioritize Targets (CD19, CD20, CD22) for Bispecific Antibodies and CAR-T in Acute Lymphoblastic Leukemia
    Demin, Oleg, Jr.
    Nikitich, Antonina
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2017, 44 : S67 - S67
  • [46] Safety and Efficacy of CD22 and CD19 Chimeric Antigen Receptor T Cell Treatment Bridging to Autologous Stem Cell Transplantation As Consolidation Therapy for B-Cell Acute Lymphoblastic Leukemia
    Qiu, Yan
    Qian, Chong-Sheng
    Zhou, Hai-Xia
    Xu, Ming-Zhu
    Kang, Li-Qing
    Sun, Ai-Ning
    Wu, De-Pei
    Yu, Lei
    Xue, Shengli
    BLOOD, 2022, 140 : 10337 - 10338
  • [47] CD19/CD22 bispecific CAR-T cells for MRD-positive adult B cell acute lymphoblastic leukemia: a phase I clinical study
    Jiahua Niu
    Huiying Qiu
    Fang Xiang
    Lin Zhu
    Jun Yang
    Chongmei Huang
    Kun Zhou
    Yin Tong
    Yu Cai
    Baoxia Dong
    Yuan Lu
    Xuedong Sun
    Liping Wan
    Xueying Ding
    Haopeng Wang
    Xianmin Song
    Blood Cancer Journal, 13
  • [48] A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy
    Yu Zhang
    Saisai Li
    Ying Wang
    Yang Lu
    Yingxi Xu
    Qing Rao
    Huijun Wang
    Haiyan Xing
    Zheng Tian
    Kejing Tang
    Lulu Lv
    Min Wang
    Jianxiang Wang
    Experimental Hematology & Oncology, 11
  • [49] A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy
    Zhang, Yu
    Li, Saisai
    Wang, Ying
    Lu, Yang
    Xu, Yingxi
    Rao, Qing
    Wang, Huijun
    Xing, Haiyan
    Tian, Zheng
    Tang, Kejing
    Lv, Lulu
    Wang, Min
    Wang, Jianxiang
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2022, 11 (01)
  • [50] DUAL CD19/CD22 CAR T CELLS SHOW FEASIBILITY IN PEDIATRIC/YOUNG ADULT B-ALL
    不详
    CANCER DISCOVERY, 2021, 11 (12) : 2958 - 2958
12345